Objective: Cardiac fibroblasts (CF) are crucial in left ventricular (LV) remodelling after myocardial infarction (MI). They predominantly express the α1 catalytic subunit of AMP-activated protein kinase (AMPKα1), while AMPKα2 is the major catalytic isoform in cardiomyocytes. AMPKα2 is known to protect the heart by preserving the energy charge of cardiac myocytes during injury, but whether AMPKα1 interferes with maladaptive heart responses remains unexplored. In this study, we aim at further substantiating the role of this AMPK isoform in the pathogenesis of post-MI LV remodelling and more particularly in the regulation of fibrotic properties of CF.
Results:
In the absence of AMPKα1, the CF proliferative response was increased in infarcted myocardia. It resulted in elevated levels of fibrotic factors but did not lead to excessive matrix deposition or degradation in KO infarcts. While CF proliferation was increased, expression of the myodifferentiation marker a-smooth muscle actin was decreased. This faulty maturation of myofibroblasts might derive from down-regulation of the transforming growth factor-β1/p38 mitogen-activated protein kinase pathway in KO infarcts. Although infarct size was similar in KO and WT hearts subjected to MI, these changes resulted in defective scar collagen maturation. This was associated with an exacerbated adverse remodelling as indicated by increased LV diastolic dimension 30 days after MI.
Conclusion:
Our data genetically demonstrate the centrality of AMPKα1 in post-MI scar formation and highlight the specificity of this catalytic isoform in cardiac fibroblast/myofibroblast biology.
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A screening strategy to identify modulators of the mitochondrial ADP/ATP translocase (ANT) for cardioprotection Claire Nicolas (1), Mathieu Porceddu (2), Nelly Buron (2), Zhenyu Wang (1), Claire Colas (3), Bogdan Iorga (3), Yves Ambroise (4), Gregoire Vandecasteele (1), Rodolphe Fischmeister (1), Annie Borgne-Sanchez (2), Catherine Brenner (1) (1) Inserm U769, Châtenay-Malabry, France -(2) Mitologics SAS, Paris, France -(3) CNRS UPR 2301, Gif Sur Yvette, France -(4) iBiTec-S -SCBM, Saclay, France In many pathological conditions, a sudden lack of energy, accompanied by an increased reactive oxygen (ROS) level and calcium overload, accelerates cell death with necrotic features. As the mitochondrion is the main source of cellular ATP and ROS, it has become an attractive therapeutic target for human pathology such as cardiac, neuronal and hepatic ischemia-reperfusion injury. In this context, we and others have shown that pharmacological modulation of ANT can prevent three acute pathologies in mice 1 and recently, we hypothesized that activation of ANT might be an innovative strategy for cardioprotection. Here, we present the design and the implementation of enzymatic, cellular and subcellular assays and their optimization for the screening of modulators of ANT (i.e. inhibitors and/or activators). We miniaturized the ADP/ATP exchange measurement in cardiac interfibrillar and subsarcolemmal isolated mitochondria from rat heart, evaluated its robustness (Z-factor) in 96 well-microtiter plates and screened an in silico-generated library of ANT-potential ligands and small molecules, i.e. about 100 molecules. Cytotoxicity was evaluated in rat H9c2 and human HT29 cell lines and non-cytotoxic compounds (i.e. with LD50 >200 μM) were selected for further studies. To confirm potential hits activity directly on ANT, we purified the native protein from rat hearts in the presence of Triton X-100, confirmed its purity by western-blot and incorporated it into small unilamellar vesicles (100 nm of diameter) as described. 2 Validation of a novel ANTcontaining proteoliposome bioluminescent assay is currently on-going to develop a method to quantify the ability of molecules to modulate ADP/ATP exchange efficacy in dose-response and calculate EC 50 . If robust, this assay will be adapted to our high throughput screening platform. For a therapeutic perspective, identified molecules will be evaluated for their toxicity, druggability, and for their ability to influence the disease outcome in animal models as a prerequisite for future clinical studies.
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Glucagon-like peptide 1 or GLP-1 counteracts NADPH oxidase activation during hyperglycemia through an AMPK-dependent pathway in adult cardiomyocytes
Magali Balteau (1), Anne Van Steenbergen (1), Chantal Dessy (2), Jean-Louis Vanoverschelde (1), Sandrine Horman (1), Louis Hue (1), Luc Bertrand (1), Christophe Beauloye (1) (1) Université catholique de Louvain (UCL), IREC, Recherche cardiovasculaire, Bruxelles, Belgique -(2) Université catholique de Louvain, IREC, Pharmacothérapie et thérapeutique, Bruxelles, Belgique Background and objective: Exposure to high glucose (HG) stimulates NADPH oxidase (NOX2) dependent-ROS production in cardiomyocytes. NOX2 activation is not triggered by an increased glucose metabolism but results from a glucose transport through a sodium-glucose co-transporter (SGLT). The aim of this work is to identify potential therapeutic approaches to counteract glucotoxicity.
Methods and results:
Primary cultures of adult rat cardiomyocytes were exposed to high glucose concentration (HG, 21mM). AMP-activated protein kinase (AMPK) activation by A769662 or Phenformin nearly suppressed ROS production under hyperglycemia. GLP-1, a new anti-diabetic drug, exerted a similar effect, blocking hyperglycemia-mediated ROS production. Interestingly, GLP-1 treatment induced a AMPK activation, the maximal activation being observed at 100 nM. α2AMPK, the major isoform expressed in cardiomyocytes (but not α1AMPK) was activated in response to GLP-1. Anti-ROS properties of AMPK were not related to change in glucose uptake or glycolysis. Using in situ proximity ligation assay technology, we demonstrated that AMPK activation prevented p47phox translocation to the caveolar structure after high glucose concentration exposure, whatever the AMPK activators used. NOX2 activation by α-methyl-D-glucopyranoside, a glucose analog exclusively transported through SGLT, or by Angiotensin 2 was also counteracted by GLP-1. The crucial role of AMPK in limiting glucotoxicity was demonstrated by overexpressing a constitutively active form of AMPK using adenoviral infection. This overexpression prevented NOX2 activation in response to HG. Finally, in mice cardiomyocytes, GLP-1 did not exert protective action in the absence of α2AMPK.
In conclusion, GLP-1 induces α2AMPK activation and blocks HG-induced p47phox translocation to the plasma membrane, limiting glucotoxicity.
The estrogen receptor alpha C451 palmitoylation site is absolutely required for vascular membrane-initiated action of estrogens in mice
Marine Adlanmerini (1), Romain Solinhac (1), Anne Abot (1), Aurélie Fabre (1), Isabelle Raymond-Letron (2), Anne-Laure Guihot (3), Frédéric Boudou (1), Lucile Sautier (2), Emilie Vessieres (3), Sung-Hoon Kim (4), Phillippe Lière (5), Coralie Fontaine (1), Andrée Krust (6), Pierre Chambon (6), John A. Katzenellenbogen (4), Pierre Gourdy (1), Philippe W. Shaul (7), Daniel Henrion (3), Jean-François Arnal (1), Françoise Lenfant (1) (1) Inserm U1048, Université de Toulouse, Toulouse, France -(2) ENVT, Université de Toulouse, Toulouse, CNRS UMR 6214, Université d'Angers, Angers, Estrogen Receptor alpha (ERα) activation functions AF-1 and AF-2 classically mediate gene transcription in response to estradiol (E2). A fraction of ERα is targeted to plasma membrane and elicits membrane-initiated steroid signalling (MISS), but the physiological roles of MISS in vivo are poorly understood. We therefore generated a mouse with a point mutation of the palmitoylation site of ERα (C451A-ERα) to obtain membrane-specific loss-offunction of ERα.
The abrogation of membrane localization of ERα in vivo was confirmed in primary hepatocytes, and it resulted in female infertility with abnormal ovaries lacking corpora lutea and increase in luteinizing hormone levels. In contrast, E2 action in the uterus was preserved in C451A-ERα mice and endometrial epithelial proliferation was similar to wild-type. However, E2 vascular actions such as rapid dilatation, the acceleration of endothelial repair and endothelial NO synthase phosphorylation were abrogated in C451A-ERα mice. A complementary mutant mouse lacking the transactivation function AF-2 of ERα (ERα-AF2°) provided selective loss-of-function of nuclear ERα actions. In ERα-AF2°, the acceleration of endothelial repair in response to estrogendendrimer conjugate, which is a membrane-selective ER ligand, was unaltered, demonstrating integrity of MISS actions. In genome-wide analysis of uterine gene expression, the vast majority of E2-dependent gene regulation was abrogated in ERα-AF2° whereas in C451A-ERα it was nearly fully preserved, indicating that membrane-to-nuclear receptor crosstalk in vivo is modest in the uterus.
Thus, this work is the first to genetically segregate membrane versus nuclear actions of a steroid hormone receptor and to demonstrate their in vivo tissue-specific roles.
